NASDAQ:PLXP - PLx Pharma Stock Price, Forecast & News

PLx Pharma trades on the NASDAQ under the ticker symbol "PLXP."

PLx Pharma Inc (NASDAQ:PLXP) issued its quarterly earnings data on Friday, November, 8th. The biotechnology company reported ($0.46) earnings per share (EPS) for the quarter, beating the Zacks' consensus estimate of ($0.50) by $0.04. The biotechnology company had revenue of $0.04 million for the quarter, compared to analyst estimates of $0.18 million. View PLx Pharma's Earnings History.

PLx Pharma is scheduled to release their next quarterly earnings announcement on Friday, March 13th 2020. View Earnings Estimates for PLx Pharma.

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for PLx Pharma in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for PLx Pharma.

Media stories about PLXP stock have been trending negative on Saturday, according to InfoTrie Sentiment. InfoTrie rates the sentiment of press coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. PLx Pharma earned a media sentiment score of -2.0 on InfoTrie's scale. They also assigned headlines about the biotechnology company a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an effect on the company's share price in the near future. View News Stories for PLx Pharma.

Some companies that are related to PLx Pharma include Kezar Life Sciences (KZR), Nature's Sunshine Products (NATR), Athersys (ATHX), Five Prime Therapeutics (FPRX), Scpharmaceuticals (SCPH), Fortress Biotech (FBIO), Evelo Biosciences (EVLO), TAIWAN LIPOSOME/S (TLC), Chiasma (CHMA), Strongbridge Biopharma (SBBP), Spero Therapeutics (SPRO), GlycoMimetics (GLYC), Akorn (AKRX), Ovid Therapeutics (OVID) and Neptune Wellness Solutions (NEPT).

Based on aggregate information from My MarketBeat watchlists, some companies that other PLx Pharma investors own include Energy Transfer LP Unit (ET), NewLink Genetics (NLNK), CBL & Associates Properties (CBL), Cornerstone Strategic Value Fund (CLM), Abeona Therapeutics (ABEO), CymaBay Therapeutics (CBAY), Corbus Pharmaceuticals (CRBP), Martin Midstream Partners (MMLP), Viking Therapeutics (VKTX) and Arlington Asset Investment (AI).

(PLXP) raised $68 million in an initial public offering on Thursday, February 4th 2016. The company issued 3,800,000 shares at a price of $17.00-$19.00 per share. Raymond James served as the underwriter for the IPO and Maxim Group LLC and Janney Montgomery Scott were co-managers.

PLx Pharma's stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include University of Texas Texas AM Investment Managment Co. (0.68%). Company insiders that own PLx Pharma stock include Michael J Valentino and Park West Asset Management Llc. View Institutional Ownership Trends for PLx Pharma.

PLXP stock was acquired by a variety of institutional investors in the last quarter, including University of Texas Texas AM Investment Managment Co.. Company insiders that have bought PLx Pharma stock in the last two years include Michael J Valentino and Park West Asset Management Llc. View Insider Buying and Selling for PLx Pharma.

Shares of PLXP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of PLXP stock can currently be purchased for approximately $5.63.

PLx Pharma has a market capitalization of $51.51 million and generates $750,000.00 in revenue each year. The biotechnology company earns $900,000.00 in net income (profit) each year or ($1.35) on an earnings per share basis. PLx Pharma employs 12 workers across the globe.View Additional Information About PLx Pharma.

The official website for PLx Pharma is http://www.plxpharma.com/.

PLx Pharma's mailing address is 9 Fishers Lane Suite E, Sparta NJ, 07871. The biotechnology company can be reached via phone at 713-842-1249 or via email at [email protected]